168 results
Page 2 of 9
8-K
EX-10.2
1o86 a8ki3kqs7r
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
2c32s8v kf5z7
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
uxwe6
22 May 23
Business combination disclosure
7:01am
8-K
qymbu g5owt
22 May 23
Other Events
6:59am
424B3
14lvx qatl4bi175
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
2pl8u6dhzeu
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-5.1
xi1owmhylehybev 1d5
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
3h2114zoq0aqmd2v
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
n8u 7t53x
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
8241elt5ag1lac
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am
8-K
EX-99.1
z8icl fq0x9n
9 May 22
Adaptimmune Reports First Quarter Financial Results and Business Update
7:40am
8-K
8kmw akzjrz
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.1
eulyil srtdp4i90vksl
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
424B5
lazf 7uivoh2llvs5is
28 Apr 22
Prospectus supplement for primary offering
8:09am